Systematic review and meta-analysis of post-transplant lymphoproliferative disorder in lung transplant recipients
- PMID: 29517815
- PMCID: PMC5992057
- DOI: 10.1111/ctr.13235
Systematic review and meta-analysis of post-transplant lymphoproliferative disorder in lung transplant recipients
Abstract
A systematic review of papers in English on post-transplant lymphoproliferative disorder (PTLD) in lung transplant recipients (LTR) using MEDLINE, EMBASE, SCOPUS, and Cochrane databases was performed. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations were strictly adhered to. Pooled odds ratios (pOR) were calculated from a random-effects model, and heterogeneity among studies was quantitated using I2 values. Fourteen studies published from 2005 to 2015 were included in the meta-analysis. One hundred and sixty-four lung transplant recipients were included. LTRs who received single vs bilateral were associated with a 7.67-fold risk of death after PTLD (6 studies with 64 LTRs; pOR 7.67 95% CI 1.98-29.70; P = .003). pOR of death for early onset PTLD (<1 year post-LT) vs late onset (>1 year post-LT) was not different (3 studies with 72 LTRS; pOR 0.62, 95% CI 0.20-1.86, P = .39). Standardized mean difference (SMD) in time from transplant to PTLD onset between LTRs who died vs alive was not different (9 studies with 109 LTRs; SMD 0.03, 95% CI -0.48-0.53, P = .92). Survival in polymorphic vs monomorphic PTLD and extranodal vs nodal disease was similar (4 studies with 31 LTRs; pOR 0.44, 95% CI 0.08-2.51; P = .36. 6 studies with 81 LTRs; pOR 1.05 95% CI 0.31-3.52, P = .94). This meta-analysis demonstrates that single LTRs are at a higher risk of death vs bilateral LTRs after the development of PTLD.
Keywords: lung transplant; malignancy; meta-analysis; post-transplant lymphoproliferative disorder.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors have no relevant financial or commercial interests in the manufacturers or distributors of any products mentioned, or any corporate funding or affiliations.
Figures
Similar articles
-
Incidence and outcome of post-transplant lymphoproliferative disorders in lung transplant patients: Analysis of ISHLT Registry.J Heart Lung Transplant. 2020 Oct;39(10):1089-1099. doi: 10.1016/j.healun.2020.06.010. Epub 2020 Jun 20. J Heart Lung Transplant. 2020. PMID: 32654913 Free PMC article.
-
Post-transplant lymphoproliferative disease in lung transplantation: A nested case-control study.Clin Transplant. 2017 Jul;31(7). doi: 10.1111/ctr.12983. Epub 2017 May 8. Clin Transplant. 2017. PMID: 28383790
-
Epstein-Barr virus primary mismatching and HLA matching: key risk factors for post lung transplant lymphoproliferative disease.Transplantation. 2004 Jul 27;78(2):205-10. doi: 10.1097/01.tp.0000128611.71038.0c. Transplantation. 2004. PMID: 15280679
-
Lung retransplantation after posttransplantation lymphoproliferative disorder (PTLD): a single-center experience and review of literature of PTLD in lung transplant recipients.J Heart Lung Transplant. 2005 Jun;24(6):671-9. doi: 10.1016/j.healun.2004.04.011. J Heart Lung Transplant. 2005. PMID: 15949726 Review.
-
Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review and meta-analysis.Crit Rev Oncol Hematol. 2018 Dec;132:27-38. doi: 10.1016/j.critrevonc.2018.09.007. Epub 2018 Sep 19. Crit Rev Oncol Hematol. 2018. PMID: 30447925
Cited by
-
Idiopathic pulmonary fibrosis lung transplant recipients are at increased risk for EBV-associated posttransplant lymphoproliferative disorder and worse survival.Am J Transplant. 2020 May;20(5):1439-1446. doi: 10.1111/ajt.15756. Epub 2020 Jan 22. Am J Transplant. 2020. PMID: 31874120 Free PMC article.
-
Medical Complications of Lung Transplantation.J Chest Surg. 2022 Aug 5;55(4):338-356. doi: 10.5090/jcs.22.066. J Chest Surg. 2022. PMID: 35924543 Free PMC article.
-
Non-pulmonary complications after lung transplantation: part II.Indian J Thorac Cardiovasc Surg. 2022 Jul;38(Suppl 2):290-299. doi: 10.1007/s12055-021-01231-z. Epub 2021 Oct 12. Indian J Thorac Cardiovasc Surg. 2022. PMID: 35756956 Free PMC article. Review.
-
Malignancy after lung transplantation.Ann Transl Med. 2020 Mar;8(6):416. doi: 10.21037/atm.2020.02.126. Ann Transl Med. 2020. PMID: 32355860 Free PMC article. Review.
-
Lung Cancer in Lung Transplant Recipients: Clinical, Radiologic, and Pathologic Characteristics and Treatment Outcome.J Comput Assist Tomogr. 2023 Jul-Aug 01;47(4):590-597. doi: 10.1097/RCT.0000000000001466. Epub 2023 Mar 9. J Comput Assist Tomogr. 2023. PMID: 36944140 Free PMC article.
References
-
- Chambers DC, Yusen RD, Cherikh WS, et al. The registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult lung and heart-lung transplantation report–2017; focus theme: allograft ischemic time. J Heart Lung Transplant. 2017;36(10):1047–59. - PubMed
-
- Burns DM, Crawford DH. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease. Blood Rev. 2004;18(3):193–209. - PubMed
-
- Paranjothi SM, Yusen RD, Krause MD, Lynch JP, Patterson GA, Trulock EP. Lymphoproliferative disease after lung transplantation: comparison of early and late cases. J Heart Lung Transplant. 2001;20(10):1054–63. - PubMed
-
- Levine SM, Angel L, Anzueto A, et al. A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipients. Chest. 1999;116:1273–77. - PubMed
-
- Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor to posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant. 1995;14:214–21. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical